Friday 31st October 2003 |
Text too small? |
The shares investors bought at $2.50 in September 2001 are trading at $1.86 but well above their low of $1.10 last year.
The company has benefited from an increase in patients opting for private medical and surgical attention as public hospitals grapple with unconscionable waiting lists.
It has made no secret of it also looking to benefit from an ageing population, pitting the business squarely in the healthcare sector.
Profit for the year ended March 31 increased 16% to $793,000 after absorbing $258,000 in unusual costs associated with a Securities Commission inquiry into the company's prospectus and listing.
Since then it has appointed former PricewaterhouseCoopers senior manager John Dixon as chief executive and has acquired local counterpart Bowen Hospital.
The improvement coincides with Sir Selwyn Cushing's family trust acquiring a 5% stake.
Wakefield will be looking to consolidate its gains while extracting all it can from the Bowen acquisition. The company is forecasting a "significant increase" in net profit for the 2004 year and should achieve that if patient numbers continue at present levels.
No comments yet
PaySauce Quarterly Market Update - Dec 2024
CHI - FY24 Results Date and Audio Conference Details
AIA - December 2024 Monthly traffic update
January 15th Morning Report
PF - Details of Interim Results Webcast
Scott Secures NZ$18 million in Global Contracts for Protein
January 14th Morning Report
AFT - NEW YEAR LETTER TO INVESTORS
TruScreen Invited to Present WHO AI Collaboration Meeting
January 13th Morning Report